The first major rewrite since 2015 sorts therapies by mechanism of action, splits care into reactive and proactive phases, and adds guidance on 2 newer Janus kinase (JAK) inhibitors.

Adapted from a human eczema survey, the 0-to-30 scale proved consistent and responsive to change, though it fell short on ear disease.

New treatment guidelines, a genetic first in cats, and fresh options in anesthesia make up the first half of our countdown of the year’s most-read stories.